Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1447024

Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Description:
Lexicon Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Lexicon Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lexicon Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Lexicon Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Lexicon Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Lexicon Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Lexicon Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Lexicon Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Lexicon Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Lexicon Pharmaceuticals, Inc. and identify potential opportunities in those areas.
 
Contents:

List of Tables
List of Figures
Lexicon Pharmaceuticals, Inc. Snapshot
Lexicon Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Lexicon Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Lexicon Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Lexicon Pharmaceuticals, Inc. – Pipeline Products Glance
Lexicon Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Lexicon Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Lexicon Pharmaceuticals, Inc. – Drug Profiles
LX1031
Product Description
Mechanism of Action
R&D Progress
LX1032
Product Description
Mechanism of Action
R&D Progress
LX2931
Product Description
Mechanism of Action
R&D Progress
LX4211
Product Description
Mechanism of Action
R&D Progress
ANGPTL4 Antibody Program
Product Description
Mechanism of Action
R&D Progress
LX7101
Product Description
Mechanism of Action
R&D Progress
LG843
Product Description
Mechanism of Action
R&D Progress
Lexicon Pharmaceuticals, Inc. – Pipeline Analysis
Lexicon Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Lexicon Pharmaceuticals, Inc. Pipeline Products By Target
Lexicon Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Lexicon Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Lexicon Pharmaceuticals, Inc. – Recent Pipeline Updates
Lexicon Pharmaceuticals, Inc. - Dormant Projects
Lexicon Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
LX6171
Lexicon Pharmaceuticals, Inc. – Company Statement
Lexicon Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 21, 2010: Lexicon Announces Encouraging Data From Phase IIa Study Of LX4211 For Type 2 Diabetes
Jun 15, 2010: Lexicon To Present Clinical Data Of LX4211 At Two Healthcare Conferences
May 05, 2010: Lexicon Presents Positive Outcome In IBS Patients Treated With LX1031
Apr 27, 2010: Lexicon To Present Phase II Clinical Data For IBS Drug Candidate At Digestive Disease Week
Jan 28, 2010: Lexicon Hosts Conference Call To Review Top-Line Phase 2 Results Of LX4211 For The Treatment Of Type 2 Diabetes Mellitus
Jan 20, 2010: Lexicon Pharmaceuticals Announces Phase 2 Trial Results Of LX4211
Nov 23, 2009: Lexicon Presents Positive Top-Line Phase II Results For LX1031 In Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
Nov 12, 2009: Lexicon Announces Positive Phase II Results Of LX1031 In Non-Constipating Irritable Bowel Syndrome
Sep 15, 2009: Exicon Initiates Phase 2 Clinical Trial Of LX4211
Aug 05, 2009: Initiation Of Phase 2 Clinical Trial Of LX2931 For Rheumatoid Arthritis Treatment
Financial Deals Landscape
Lexicon Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Lexicon Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Lexicon Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Lexicon Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
Lexicon Pharmaceuticals Completes Public Offering Of $57 Million
Lexicon Pharmaceuticals Completes Private Placement Of $205 Million
Lexicon Completes Private Placement Of $40 Million
Lexicon Completes Issue Of $3.67 million
BioSeek Enters Into Research Agreement With Lexicon Pharmaceuticals
Nuevolution Enters Into Co-Development Agreement With Lexicon Pharmaceuticals
Lexicon Enters Into Co-Development Agreement With Symphony
Lexicon Extends Collaboration With Bristol-Myers
Takeda Enters Into Co-Development Agreement With Lexicon
Lexicon Expands Collaboration With Genentech
Lexicon Enters Into Collaboration Agreement With XOMA
Lexicon Enters Into Agreement With Organon
Lexicon Enters Into Collaboration Agreement With Takeda
XOMA Terminates Co-Development Agreement With Lexicon Pharmaceuticals
Licensing Agreements
Lexicon Pharmaceuticals Enter Into License Agreement With Cellectis
Lexicon Expands Its Licensing Agreement With Stem Cell
Lexicon Enters Into Licensing Agreement With Johnson & Johnson
Lexicon Extends Licensing Agreement With Roche
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1447024

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Sep 17th 2014
8:58:33 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Lexicon Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1447024

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Sep 17th 2014
8:58:33 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)